News Updates
Scope

Thu, May 28, 2026

1 updates
ZBIO
7:05 AM

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the

Presentation / Abstract • Phase 3EULAR 2026 oral presentation Thu, Jun 4, 2026zenasbio.com

Tue, May 19, 2026

1 updates
ZBIO
7:05 AM

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a

Presentation / Abstract • Phase 3Oral presentation Thu, Jun 4, 2026, 2:45 PM GMTzenasbio.com

Mon, May 18, 2026

1 updates

Wed, May 13, 2026

2 updates
ZBIO
6:50 AM

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - - Phase 1 SAD and MAD data expected by year-end 2026, with proof-of-concept data in psoriasis patients

Trial Start • Phase 1Trial initiation Wed, May 13, 2026zenasbio.com
ZBIO
6:00 AM

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – – Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 – – Obexelimab

Presentation / Abstract • Phase 3EULAR oral presentation Thu, Jun 4, 2026zenasbio.com

Fri, Apr 17, 2026

1 updates

Fri, Mar 27, 2026

1 updates
ZBIO
12:12 AM

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients

zenasbio.com

Thu, Mar 26, 2026

1 updates

Mon, Mar 16, 2026

2 updates